Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 24 clinical trials
Featured trial
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation

Evaluates the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of MRTX849 in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 is an orally-available small molecule inhibitor of KRAS G12C.

advanced solid tumor
solid tumor
malignant solid tumor
  • 538 views
  • 22 Nov, 2021
  • 62 locations
JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard Therapy

This study is a multi-center, open-label, phase Ib study to evaluate the safety, tolerability and efficacy of JMT101 combined with afatinib in patients with advanced esophageal squamous cell

  • 0 views
  • 26 Dec, 2021
  • 5 locations
An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR a HER2 or a HER3 Mutation

Objective(s):To investigate the efficacy and safety of afatinib in EGFR, HER 2 and HER3 mutated cancers, regardless of cancer type, excluding EGFR mutated non-small cell lung cancer.

  • 1 views
  • 22 Jan, 2021
  • 5 locations
Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

immune checkpoint inhibitor. The primary objective is to evaluate the efficacy of the combination of cetuximab and afatinib.

  • 42 views
  • 24 Mar, 2022
  • 1 location
Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer

There is no report afatinib plus bevacizumab in the treatment of EGFR G719X, S768I, and L861Q single or compond mutation of metastatic non-small-cell lung cancer (NSCLC). The purpose of this

  • 0 views
  • 10 Mar, 2022
  • 1 location
Primary Tumor Resection With EGFR TKI for Stage IV NSCLC

Our project is going to enroll patients with stage IV NSCLC with EGFR mutation and evaluate whether primary tumor resection after receiving the afatinib can prolong survival. This project is

  • 0 views
  • 09 Apr, 2022
  • 2 locations
A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer (FWD1509)

The purpose of this study is to characterize the safety and tolerability of FWD1509 MsOH in advanced NSCLC patients and establish the maximum tolerable dose (MTD), recommended phase 2 dose (RP2D) in advanced NSCLC patients.

HER2
neutrophil count
measurable disease
erbb2
EGFR
  • 0 views
  • 04 Oct, 2022
  • 1 location
Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC:Prospective Study (SELECT-2)

This is a nationwide, multicenter and prospective cohort study. The purpose of this study is to evaluate the synergistic effect and safety of Elemene plus TKIs in EGFR-mutated advanced non-small cell lung cancer.

administration intravenous
lung cancer
icotinib
erlotinib
gefitinib
  • 0 views
  • 11 Jul, 2022
  • 7 locations
Afatinib in Advanced Refractory Urothelial Cancer

This phase II trial studies how well afatinib dimaleate works in treating patients with urothelial cancer that cannot be removed surgically and has grown after treatment with standard first-line

HER2
measurable disease
glomerular filtration rate
metastasis
metastatic urothelial carcinoma
  • 29 views
  • 07 Oct, 2021
  • 5 locations
Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity (DARWIN1)

To assess if targeting activating EGFR and HER2 mutations in Non-Small Cell Lung Cancer (NSCLC) is more effective when these mutations are truncal dominant mutations (50%), as opposed to non-dominant (5 to <50%) or low frequency mutations (<5%). This trial will be available to patients registered to the TRACERx study …

secondary malignant neoplasm of liver
targeted therapy
HER2
neutrophil count
measurable disease
  • 31 views
  • 24 Jan, 2022
  • 6 locations